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Abstract 
Background: Hyperlipidemia is one of the major risk factors for developing a cardiovascular 
disease (CVD) and it is a frequent post-transplant complication, occurring in up to 60% of the 
renal transplant recipients (RTRs). Lipid lowering therapy with HMG-CoA reductase 
inhibitors (statins) is generally recommended and may reduce the overall cardiovascular risk. 
The aim of this study was to evaluate the lipid profile, statin administration and their 
relationship with arterial stiffness parameters in renal transplant recipients.  
Methods: Three hundred and forty-four stable RTRs (62.5% male) transplanted between 
1994 and 2018 were randomly enrolled to the study. The following parameters of arterial 
stiffness was measured in each patient: carotid femoral pulse wave velocity (baPWV left and 
right, cfPWV) and pulse pressure (PP right and left). The study group was divided based on 
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the use statins: 143 (41.6%) and 201 (58.4%). RTRs were qualified to the statin (+) and the 
statin (–) group, respectively. 
Results: In the statin (+) as compared to statin (–) group there were more patients with a 
CVD (32.9% vs. 14.9%) and diabetes (25.2% vs. 14.4%). In the whole study group, CVD was 
associated with a significant increase of both baPWV and cfPWV as well as PP (8.5 mmHg). 
There were significant differences in arterial stiffness parameters (baPWV, cfPWV, PP) 
between the statin (+) and the statin (–) group.  
Conclusions: Arterial stiffness was increased in RTRs with CVD and hyperlipidemia. The 
control of hyperlipidemia was poor in RTRs. 
Key words: arterial stiffness, kidney transplantation, statin, hyperlipidemia 
 
 
Introduction 
In spite of the improvement in rejection rates long-term survival in renal transplant 
recipients (RTRs) has remained unchanged and cardiovascular disease (CVDs) are a major 
cause of death in this patient population [1, 2]. Moreover, hyperlipidemia is the major 
cardiovascular (CV) risk factor and is a frequent post-transplant complication, occurring in up 
to 60% of the patients [1, 3, 4]. Lipid lowering therapy statins reduce the cardiovascular risk 
in patients after kidney transplantation [5, 6]. 
Saran et al. [7] showed that: “the occurrence of CVDs in kidney transplant recipients 
is affected not only by the traditional risk factors but also by immunosuppressive therapy, 
earlier dialysis therapy, proteinuria, inflammation or anemia. All these factors lead to 
increased arterial stiffness [8, 9]. 
Carotid-femoral pulse wave velocity (PWV), as an arterial stiffness parameter, is an 
independent predictor of CV complications in the general population and high CV patients 
[10, 11]. Statins treatment mitigates an arterial stiffness, beyond their effects on the lipid 
profile [10]. Additionally, lipid lowering treatment has pleiotropic effects by enhancing nitric 
oxide bioavailability, antioxidant effect, and interaction with the renin–angiotensin–
aldosterone (RAA) system [10, 12]. There are no essential data available concerning the 
influence of statins on arterial stiffness in RTRs. The main aim of the study was to evaluate 
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the lipid profile, statin administration and their relationship to arterial stiffness parameters in 
renal transplant recipients.  
 
Methods 
This cross-sectional study enrolled 344 stable RTRs, transplanted between 1994 and 
2018, who attended the outpatient unit of the Department of Nephrology Charité – 
Universitätsmedizin Berlin, Germany, between February and July 2018. 
Patients gave their written informed consent. The study was conducted in accordance 
with the Declaration of Helsinki.  
Demographic and clinical information including: renal transplant, CV and diabetic 
status was analyzed. Additionally, the immunosuppressive protocol, hypertensive and statin 
treatment were assessed. Data concerning serum creatinine, potassium concentration, 
hemoglobin, proteinuria, albuminuria and lipids levels refer to a single assessment obtained 
from medical files of patients.   
Furthermore, we investigated the following parameters of arterial stiffness: brachial 
ankle and carotid femoral pulse wave velocity (baPWV left and right, cfPWV), ankle brachial 
index (ABI) and also blood pressure (BP), pulse pressure (PP) in each patient using ABI 
system 100 (Boso Bosch and Sohn Germany). Additionally, pulsatile stress test (left and 
right), as a marker of arterial stiffness was assessed using the equation: pulsatile stress test = 
heart rate × pulse pressure. 
 
Statistical analyses 
Statistical analyses were performed using the STATSTICA 13.3 PL for Windows 
software package. Categorical variables are presented as absolute numbers (percentages). 
Continuous variables are presented as mean value ± standard deviation (SD) or as median and 
interquartile range (IQR) for highly skewed variables. Differences in the distribution of 
continuous variables were assessed using the two-sample t-test or the Mann-Whitney U-test, 
respectively. The χ2 test was used for the categorical variables. Correlation coefficients were 
calculated using the Spearman test. Additionally, a simple linear regression model was used to 
model the relationship between a scalar response (or dependent variable) and one or more 
explanatory variables (or independent variables). The Shapiro-Wilk test was used to assess 
normality. In all statistical tests, a p-value < 0.05 was considered as statistically significant. 
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Results 
Overall, 344 stable patients were enrolled to the study. The definition of stable patient 
included: constant level of creatinine and immunosuppressive drugs in the blood and the lack 
of any CV events during 6 and 12 months before enrolment to the study, respectively. 
The study population was divided in two groups based on the statin application. 143 
(41.6%) and 201 (58.4%) were qualified to the group statin (+) and statin (–), respectively. 
Overall, 86% of the RTRs under statin treatment received fluvastatin in a mean dose of 44.7 
mg/day (55.9% of the maximal dose). 7% used pravastatin in a mean dose of 30 mg (75% of 
the maximal dose), 4.9% used atorvastatin in a mean dose of 35.7 mg (44.6% of the maximal 
dose) and 2.1% used simvastatin in a mean dose of 23.3 mg (58.2% of maximal dose). 
 
Study population characteristics 
In the group of statins (+) as compared to statin (–) there were more patients with CV 
(32.9% vs. 14.9%, p < 0.05) and diabetes (25.2% vs. 14.4%, p = NS). There were more males 
and the average body mass index (BMI) was higher in the statin (+) group (p < 0.05). The 
general characteristics of the study participants are summarized in Table 1.  
The main causes of end stage renal disease (ESRD) in the study population were 
glomerulonephritis (the majority were biopsy proven, but the histopathological results weren’t 
available in patient’s files), tubulointerstitial nephropathy and polycystic kidney disease. In 
the statin (+) group the average serum creatinine was higher and estimated glomerular 
filtration rate (eGFR; CKD-EPI) was significantly lower as compared to the statin (–) group 
(p < 0.05). The level of albumin in the blood, proteinuria and albuminuria were similar in the 
statin (+) and (–) groups. 
The groups did not differ significantly with respect to the time of renal replacement 
therapy (RRT) before transplantation, but the time after transplantation was longer (88 vs. 51 
months, p < 0.05) in the statin (+) group. 
 
Immunosuppressive regimen in the study population 
Calcineurin inhibitors were used in 82.8% of the study population. Cyclosporine was 
administered in 27.3% vs. 16.9% (p < 0.05) and tacrolimus in 48.2% vs. 71.1% (p < 0.05) of 
the patients in the statin (+) and (–) group, respectively. 36.4% vs. 48.7% of the participants 
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used mycophenolate mofetil (MMF) in the statin (+) and (–) group, respectively. No 
significant differences were observed in terms of MMF/mycophenolate sodium (MPS), 
azathioprin and mammalian target of rapamycin (mTOR) agents between both groups. In the 
statin (+) cohort more patients received belatacept 17.5% vs. 8% (p < 0.05). In 59.3% of the 
participants RAA blockers were implemented. In the statin (+) and (–) group 65.7% vs. 54.7% 
of the patients received RAA blockers (p < 0.05). Beta-blockers and diuretics were prescribed 
more often in the statin (+) group (p < 0.05). 
 
The control and treatment of hypertension 
The control of systolic BP (SBP) and diastolic BP (DBP) was significantly worse in 
the statin (+) group (p < 0.05). Moreover, PP value was higher in statin (+) patients (Table 2). 
In group with lipid parameters as: low density lipoprotein (LDL) ≥ 100 mg/dL and non-high 
density lipoprotein (HDL) ≥ 130 mg/dL; SBP (p < 0.05), DBP (p = NS) and PP (p < 0.05) 
were higher as compare to group with LDL < 100 mg/dL and non-HDL < 130 mg/dL, 
respectively. The differences in SBP, DBP and PP value did not differ significantly between 
patients with the level of triglycerides ≥ 150 mg/dL and < 150 mg/dL. The statin (+) 
participants used significantly more RAA blockers, beta-blockers and diuretics (p < 0.05). No 
difference in terms of calcium channel blockers administration were noticed. 
 
Lipid parameters in study group 
The level of non-HDL and triglycerides was higher (p < 0.05) in the statin (+) group. 
No differences in total and LDL cholesterol (LDL-C) levels between statin (+) and statin (–) 
were observed. The values of HDL-cholesterol (HDL-C) differed significantly in statin (+) 
and statin (–) groups (48 vs. 53 mg/dL; p < 0.05). 
The aim of treatment of hyperlipidemia (LDL < 100 mg/dL) was achieved in 26.6% 
vs. 27.4% (p = NS) in statin (+) and statin (–) groups, respectively. In 38.3% vs. 46.3% of 
patients (p < 0.05) in statin (+) and statin (–) groups, non-HDL < 130 mg/dL was observed. 
 
Arterial stiffness in study group 
 6 
 
The values of arterial stiffness parameters (baPWV, cfPWV, PP, pulsatile stress test) 
and SBP were higher (p < 0.05) in the statin (+) as compared to the statin (–) group. There 
were no differences in terms of DBP and ABI between both groups (Table 2). 
 
Lipids, blood pressure and arterial stiffness parameters 
Patients with LDL-C level < 100 mg/dL, had better control of SBP and DBP (p < 0.05) 
as compared to LDL-C ≥ 100 mg/dL. There were significantly lower values of arterial 
stiffness parameters (PP, pulsatile stress test and cfPWV) in the group with LDL < 100 mg/dL 
(p < 0.05). No differences were observed for ABI and baPWV (Table 3). In the group with 
non-HDL-C ≥ 130 mg/dL SBP and DBP were higher. Moreover, PP right and left were 56.3 
vs. 52.2 mmHg (p = 0.07) and 56.1 vs. 51.2 mmHg (p < 0.05) in the group with non-HDL-C ≥ 
130 mg/dL and < 130 mg/dL, respectively. The arterial stiffness parameters ABI, pulsatile 
stress test, baPWV and cfPWV did not differ between both groups (Table 4). There were no 
significant differences in SBP and DBP between patients with triglycerides ≥ 150 mg/dL and 
< 150 mg/dL. The values of baPWV left and cfPWV were significantly lower in patients with 
triglycerides < 150 mg/dL. ABI, PP, pulsatile stress test and baPWV left did not differ 
between both groups (Table 5). 
 
Relationship between treatment with statins and arterial stiffness parameters 
In the statin (+) group the mean value of PP right, PP left and baPWV left was higher 
by 1.83 mmHg, 2.18 mmHg and 0.34 m/s as compared to the statin (–) group, respectively. 
The level of LDL ≥ 100 mg/dL was associated with a significant increase of PP right 
(2.33 mmHg) and PP left (2.1 mmHg) as compared to patients with LDL < 100 mg/dL. In 
patients with LDL ≥ 100 mg/dL, the pulsatile stress right and left was higher by 156 and 181 
relative to the group with LDL < 100 mg/dL, respectively. The relationship between the 
treatment with statins and arterial stiffness parameters is presented in Tables 3, 4 and 5. It is 
worth to underline, that arterial stiffness was higher in the statin (+) group. 
 
Multivariate analysis 
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Adjusted for age, sex, diabetes and CV status, the pulse pressure right/left measured in 
both groups, the value was higher in the statin (+) group, but the difference was not 
statistically significant. Similar results were attained for participants with non-HDL ≥ 130 
mg/dL vs. < 130 mg/dL and LDL ≥ 100 mg/dL vs. < 100 mg/dL. 
 
Discussion 
Statin treatment, lipids level and cardio- and renal protection in RTRs 
A protective effect of statin treatment on cardiac endpoints has consistently been 
confirmed in different populations [13]. Statins protect nephrological patients from CV 
complications, but the effect is lower in groups with severe renal failure [14]. However, 
although cardio- and reno-protective effects of statins have been well documented in the 
general population, the effects have been less studied in RTRs. Moreover, only 36% of RTRs 
are treated with statins according to Clinical Practice Guidelines for Managing Dyslipidemias 
in Kidney Transplant Patients [15]. The results of the Assessment of Lescol in Renal 
Transplantation (ALERT) study, showed that fluvastatin (40 mg/day) decreased the level of 
LDL-C by 32%. On the other hand, the primary endpoint composed of cardiac death, nonfatal 
myocardial infarction or coronary intervention procedure, was reduced by 17%, but this 
difference was not statistically significant [14]. Moreover, the outcomes revealed that only 
41.6% of participants used statins [14]. The present study showed that treatment with statins 
was insufficient, because only 26.6% of the RTRs achieved the main aim of hypolipidemic 
treatment (LDL < 100 mg/dL). It should be underlined, that on average, patients received 
between 44.6% and 75% of the maximal dose of statins (atorvastatin, fluvastatin, simvastatin, 
pravastatin). 
Statins are known to have pleiotropic effects such as anti-inflammatory, 
antiproliferative, and immunosuppressive effects, which suggested their possible impact on 
acute allograft rejection [16]. Regarding vascular remodelling, interstitial fibrosis, and tubular 
atrophy (IF-TA) intensive statin treatment may halt the progression of IF-TA protecting it 
from atherosclerosis [17, 18]. The beneficial effects of statins on coronary atherosclerosis 
progression have been attributed not only to lipid-lowering effects, but probably also to their 
anti-inflammatory properties. Furthermore, nephroprotective aspects of statins have been 
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ascribed to regulate fibrogenic mechanisms and their effect on endothelial dysfunction [19]. 
Cochrane meta-analysis showed in 22 studies, that statins may reduce the relative risk of CV 
events in RTRs [20].   
Relationship between lipids, blood pressure and arterial stiffness parameters 
Pulse wave velocity and PP are a non-invasive method to assess a central arterial 
stiffness that predicts independently CVD morbidity and mortality [21]. Increased PWV 
serves as target organ damage in subjects with hypertension and is included in risk 
stratification for CVD events [21].  
Moreover, Korogiannou et al. [22] provide an overview of the field of arterial stiffness 
in renal transplantation and the prognostic significance of arterial stiffness for CV events, 
renal events and mortality in these individuals, as well as studies examining the changes in 
arterial stiffness following renal transplantation. PWV is considered as the ‘gold standard’ 
method for the assessment of arterial stiffness [21]. Increased aortic stiffness leads to a 
premature return in heart’s late systole and increases central PP and SBP. It resulted in left 
ventricular hypertrophy, a well-established risk factor for coronary events [21]. In addition, 
PP, as the difference between SBP and DBP, is a major CV risk factor directly related to CV 
events [23]. 
In the current study values of arterial stiffness parameters (baPWV, cfPWV, PP, 
pulsatile stress test) and SBP were higher (p < 0.05) in the statin (+) as compared to the statin 
(–) group. It is worth mentioning that in the statin (+) group, there were more patients with 
diabetes, CVD and hypertension. Additionally, it is prudent  to underline, that  current 
patients with a lower level of LDL (< 100 mg/dL) and non-HDL (< 130 mg/dL), better values 
of BP and arterial stiffness parameters were observed. 
Theilade et al. [24] failed to show an independent relationship between brachial PP 
and CV events in a high-risk population with diabetes, CKD and anemia. In transplant 
patients, increased stiffness of the common carotid artery predicts the occurrence of CV 
events [25]. More recently, in RTRs, PWV was associated with the combined end point of 
doubling plasma creatinine and CV events [25]. 
Additionally, D’elia et al. [10] indicated: “a direct association between statin use and 
decreased arterial stiffness in the controlled randomized intervention trial of statin use having 
PWV changes as the main endpoint in the general population, patients with CKD, 
hypercholesterolemia, cardiovascular disease and obturative sleep apnea”. 
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Navarro-Muñoz et al. [26] showed the improvement of LDL profile after atorvastatin 
treatment in patients after kidney transplantation with worse PWV (> 9.75 m/s), transforming 
growth factor-beta 1 levels were significantly reduced after 3 months of treatment.  
 
Limitations of the study 
There are several limitations of this study that should be considered when interpreting 
the results. First, the present results do not prove direct decreasing of arterial stiffness by 
statins. Additionally, the duration of statin therapy, indications and adherence for this 
treatment were not assessed. Nevertheless, it can be considered that more intensive statin 
treatment in RTRs could mitigate aortic stiffness. Second, in spite of the fact that the study 
population was divided in statin (+) and statin (–), it was a heterogenous group, with different 
comorbidity conditions and dissimilar time of dialysis and the period after renal 
transplantation. Third, there are the limitations of using high doses of statins in renal 
transplant recipients due to interaction with calcineurin inhibitor and impaired graft function. 
Fourth, the use of office blood pressure readings, done once, to monitor the quality of 
BP control may be subject to significant error due to white-coat syndrome. In reality 
therefore, treatment results may even be better. In addition, the assessment of antihypertensive 
treatment was based on medical records. Hence, there might be small differences between 
these data and real-life data. 
However, despite these limitations, the study highlights some important information 
for the RTRs. In this matter, longer observation time are needed as well as repeated 
measurements of all arterial stiffness parameters. 
 
Conclusions 
 In summary the studied population had intended to show that the administration of 
statin was low. Additionally, hyperlipidemia was poorly controlled. On the other hand, 
arterial stiffness was lower in patients with better control of hyperlipidemia. Therefore, there 
is a necessity for more frequent lipid-lowering therapy implementation. It may contribute to 
the reduction of arterial stiffness and can result in the reduction of CV risk of RTRs. 
 
Conflict of interest: None declared 
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Table 1. Characteristics of the study population. 
 Total study 
population 
Statin (+) Statin (–) P 
RTRs 344 143 (41.6%) 201 (58.4%) < 0.05 
Sex: men 215 (62.5%) 94 (65.7%) 121 (60.2%) < 0.05 
Age [years] 52.7 ± 13.9 56.7 ± 12.0 49.8 ± 14.4 NS 
Body mass index [kg/m2] 25.62 ± 4.78  29.91 ± 5.11 24.69 ± 4.31 < 0.05 
Weight [kg] 76.16 ± 17.22 79.83 ± 17.65 73.53 ± 16.44 < 0.05 
Diabetes mellitus (any type 1, 2, NODAT) 64 (18.6%) 36 (25.2%) 29 (14.4%) NS 
Cardiovascular disease (CAD, POAD) 77 (22.4%) 47 (32.9%) 30(14.9%) < 0.05 
Hypertension 298 (86.6%) 126 (88.1%) 172 (85.5%)  NS 
Reasons of ESRD and KTx:      
Primary glomerulonephritis 186 (54.1%) 73 (55.0%) 113 (56.2%) NS 
Diabetic nephropathy  5 (1.5%) 1 (0.7%) 4 (2%) NS 
Polycystic kidney disease  56 (16.3%) 26 (18.2%) 30 (14.9%) NS 
Tubulointerstitial nephritis  70 (20.3%) 30 (20.9%) 40 (20%) NS 
Hypertensive nephropathy  18 (5.2%) 11 (7.7%) 7 (3.5%) NS 
Unknown etiology  10 (2.9%) 2 (1.4%) 8 (4%) NS 
Time of RRT [months] 58.5 (19–97) 48 (14–83) 44 (6–94) NS 
Time after KTx [months] 73 (28–140) 88 (46–161) 51 (12–89) < 0.05 
Preemptive KTx 46 (13.4%) 17 (11.9%) 29 (14.4%) NS 
sCr level [mg/dL] 1.47 (1.19–
1.92) 
1.56 (1.18–2.06) 1.44 (1.19–1.85) NS 
eGFR CKD-EPI [mL/min/1.73 m2] 50.4 ± 19.8 47.4 ± 19.9  52.4 ± 19.5 < 0.05 
Potassium [mmol/L] 4.3 ± 0.6 4.3 ± 0.58 4.3 ± 0.56 NS 
Hemoglobin [g/dL] 12.7 ± 1.7 12.9 ± 1.8 12.6 ± 1.7 NS 
Total cholesterol [mg/dL] 195 (164–222) 198 (168–222) 191 (162–221) NS 
LDL [mg/dL] 122 (99–146) 120 (100–139) 123 (98–149) NS 
HDL [mg/dL] 51 (42–64) 48 (39–63) 53 (44–66) < 0.05 
Non-HDL [mg/dL] 138 (113–166) 145 (119–171) 134 (107–165) < 0.05 
Triglycerides [mg/dL] 155 (113–221) 185 (128–256) 137 (106–195) <0.05 
LDL < 100 mg/dL 93 (27%) 38 (26.6%) 55 (27.4%) NS 
Non-HDL < 130 mg/dL 147 (42.7%) 54 (38.3%) 93 (46.3%) < 0.05 
Triglycerides < 150 mg/dL 168 (48.8%) 52 (36.4%) 116 (57.7%) < 0.05 
Albumin [g/L] 43.46 ± 3.28  43.59 ± 3.12 43.64 ± 3.09 NS 
Albuminuria [mg/day] 41.5 (9.3–145) 31 (8–176) 45 (11–145) NS 
Proteinuria [mg/day] 171 (114–380) 172 (108–365) 170 (120–385) NS 
Albuminuria [mg/g] creatinine 49 (15–156) 60 (15–203) 48 (15–136) NS 
Proteinuria [mg/g] creatinine 138 (84–322) 137 (88–357) 138 (82–321) NS 
Cyclosporine 73 (21.2%) 39 (27.3%) 34 (16.9%) < 0.05 
Tacrolimus  212 (61.6%) 69 (48.2%) 143 (71.1%) < 0.05 
Steroids  176 (51.2%) 68 (47.5%) 108 (53.4 %) NS 
Mycophenolate mofetil 150 (43.6%) 78 (36.4%) 98 (48.7%) < 0.05 
Mycophenolate sodium 171 (49.7%) 107 (54.5%) 93 (46.3%) NS 
Azathioprin  5 (1.5%) 4 (2.8%) 1 (0.5%) NS 
mTOR  10 (2.9%) 6 (4.2%) 4 (2%) NS 
Belatacept  41 (11.9%) 25 (17.5%) 16 (8%) < 0.05 
RAA system blockade  204 (59.3%) 94 (65.7%) 110 (54.7%) < 0.05 
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Calcium channel blockers  158 (45.9%) 71 (49.6 %) 87 (43.3 %) NS 
Beta-blockers  241 (70.1%) 119 (83.2%) 124 (61.7%) < 0.05 
Diuretics  120 (34.9%) 72 (50.3%) 48 (23.9%) < 0.05 
Erythropoietin stimulating agent 47 (13.7%) 31 (21.7%) 36 (17.9%) NS 
Data are show as mean ± standard deviation or number (percentage) or median (interquartile range). CAD — 
coronary artery disease; eGFR — estimated glomerular filtration rate; ESRD — end stage renal disease; HDL – 
high density lipoprotein KTx — kidney transplantation; LDL – low density lipoprotein; mTOR — mammalian 
target of rapamycin; NODAT — new onset diabetes after transplantation; POAD — peripheral obliterans artery 
disease; RAA — renin–angiotensin–aldosterone; RRT — renal replacement therapy; RTRs — renal transplant 
recipients 
 
 
Table 2. Arterial stiffness parameters and blood pressure in the study population. 
 Total study 
population 
Statin (+) Statin (–) P 
baPWV right [m/s] 11.8 (10.7–13.3) 12.0 (10.0–13.7) 11.7 (10.6–12.9) < 0.05 
baPWV left [m/s] 12.0 (10.9–13.5) 12.3 (11.2–14.4) 11.7 (10.6–13.0) < 0.05 
cfPWV [m/s] 7.9 (6.9–9.5) 8.1 (7–9.8) 7.7 (6.7–9.2) < 0.05 
SBP right arm [mmHg] 140.7 ± 17.7 143.8 ± 18.2 138.5 ± 17 < 0.05 
SBP left arm [mmHg] 139.6 ± 20.1 142.7 ± 20.4 137.4 ± 19.7 < 0.05 
DBP right arm [mmHg] 85.8 ± 10.3 86.5 ± 10.0 85.4 ± 10.4 NS 
DBP left arm [mmHg] 85.7 ± 10.9 86.2 ± 10.2 85.2 ± 10.9 NS 
PP right arm [mmHg] 54.6 ± 14.7 56.8  ± 15.0 53.1 ± 14.3 < 0.05 
PP left arm [mmHg] 54.0 ± 15.9 56.5 ± 15.7 52.1 ± 15.9 < 0.05 
Pulsatile stress right 3521 ± 1012 3599 ± 994 3469 ± 1024 < 0.05 
Pulsatile stress left 3520 ± 1225 3611 ± 1258 3454 ± 1202 < 0.05 
ABI right 1.08 ± 0.17 1.08 ± 0.23 1.09 ± 0.10 NS 
ABI left 1.09 ± 0.13 1.07 ± 0.16 1.10 ± 0.11 NS 
Data are show as mean ± standard deviation or median (interquartile range). ABI — ankle brachial index; 
baPWV — brachial ankle pulse wave velocity; cfPWV — carotid femoral pulse wave velocity; DBP — diastolic 
blood pressure; PP — pulse pressure; SBP — systolic blood pressure 
 
 
 
Table 3. Arterial stiffness parameters and blood pressure in groups with different level of 
lowdensity lipoprotein (LDL) cholesterol. 
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 LDL ≥ 100 mg/dL LDL < 100 mg/dL P 
Renal transplant recipients 251 93 < 0.05 
SBP right arm [mmHg] 141.9 ± 17.3 137.1 ± 18.2 < 0.05 
SBP left arm [mmHg] 141.9 ± 15.3 133.6 ± 19.7 < 0.05 
DBP right arm [mmHg] 86.1 ± 10.6 85.2 ± 9.1 NS 
DBP left arm [mmHg] 86.8 ± 10.2 82.5 ± 12.4 < 0.05 
Pulse pressure right 55.8 ± 15.3 51.2 ±12.4 < 0.05 
Pulse pressure left 55.1 ± 16.3 51.1 ± 14.3 0.07 
ABI right 1.08 ± 0.17 1.10 ± 0.18 NS 
ABI left 1.08 ± 0.11 1.11 ± 0.17 NS 
Pulsatile stress right  3603 ± 1054 3291 ± 853 < 0.05 
Pulsatile stress left 3324 ± 1274 3256 ± 1050 < 0.05 
baPWV right [m/s] 11.8 (10.8–13.5) 11.6 (10.6–13.3) NS 
baPWV left [m/s] 12.0 (10.9–13.8) 11.8 (10.7–13.1) NS 
cfPWV [m/s] 8.0 (7–9.5) 7.5 (6.6–8.7) < 0.05 
Data are show as mean ± standard deviation or median (interquartile range). Coversion factor for SI unit is as 
follows: for LDL divide by 38.67. ABI — ankle brachial index; baPWV — brachial ankle pulse wave velocity; 
cfPWV — carotid femoral pulse wave velocity; DBP — diastolic blood pressure; PP — pulse pressure; SBP — 
systolic blood pressure 
 
 
Table 4. Arterial stiffness parameters and blood pressure in groups with different level of 
non–high density lipoprotein (HDL) cholesterol. 
 Non–HDL ≥ 130 
mg/dL 
Non–HDL < 130 
mg/dL 
P 
Renal transplant recipients 195 149  
SBP right arm [mmHg] 142.4 ± 17.3 138.1 ± 17.8 NS 
SBP left arm [mmHg] 143.1 ± 19.1 134.7 ± 19.2 < 0.05 
DBP right arm [mmHg] 86.0 ± 10.0 85.4 ± 10.6 NS 
DBP left arm [mmHg] 87.1 ± 10.4 83.5 ± 11 < 0.05 
Pulse pressure right 56.3 ± 15.4 52.2 ±12.9 0.07 
Pulse pressure left 56.1 ± 16.3 51.2 ± 14.9 < 0.05 
ABI right 1.07 ± 0.11 1.10 ± 0.23 NS 
ABI left 1.08 ± 0.12 1.10 ± 0.14 NS 
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Pulsatile stress right 3626 ± 1119 3382 ± 843 NS 
Pulsatile stress left 3650 ± 1332 3344 ± 1058 NS 
baPWV right [m/s] 12.0 (11.0–13.3) 11.7 (10.5–13.3) NS 
baPWV left [m/s] 12.0 (10.9–13.5) 11.9 (10.6–13.8) NS 
cfPWV [m/s] 8.0 (7.2–9.4) 7.6 (6.6–9.5) NS 
Data are show as mean ± standard deviation or median (interquartile range).   Coversion factor for SI unit is as 
follows: for HDL divide by 38.67. ABI — ankle brachial index; baPWV — brachial ankle pulse wave velocity; 
cfPWV — carotid femoral pulse wave velocity; DBP — diastolic blood pressure; PP — pulse pressure; SBP — 
systolic blood pressure 
 
 
Table 5. Arterial stiffness parameters and blood pressure in groups with different level of 
triglicerydes. 
 Triglicerydes ≥ 150 
mg/dL 
Triglicerydes < 150 
mg/dL 
P 
Renal transplant recipients 175 169 NS 
SBP right arm [mmHg] 141.5 ± 17.3 139.6 ± 17.9 NS 
SBP left arm [mmHg] 140.4 ± 18.4 138.5 ± 21.5 NS 
DBP right arm [mmHg] 86.6 ± 10.0 85.9 ± 10.5 NS 
DBP left arm [mmHg] 86.3 ± 10.1 84.8 ± 11.4 NS 
Pulse pressure right 55.8 ± 15.3 53.2 ±13.9 NS 
Pulse pressure left 54.2 ± 15,1 53.6 ± 16.8 NS 
ABI right 1.08 ± 0.10 1.09 ± 0.22 NS 
ABI left 1.08 ± 0.10 1.10 ± 0.15 NS 
Pulsatile stress right 3578 ± 1056 3382 ± 843 NS 
Pulsatile stress left 3511 ± 1164 3344 ± 1058 NS 
baPWV right [m/s] 11.8 (11.0–13.7) 11.7 (10.5–12.9) NS 
baPWV left [m/s] 12.3 (11.2–13.8) 11.6 (10.6–13.2) < 0.05 
cfPWV [m/s] 8.0 (7.0–9.8) 7.6 (6.7–9.1) < 0.05 
Data are show as mean ± standard deviation or median (interquartile range).   Coversion factor for SI unit is as 
follows: for triglycerides divide by 88.7. ABI — ankle brachial index; baPWV — brachial ankle pulse wave 
velocity; cfPWV — carotid femoral pulse wave velocity; DBP — diastolic blood pressure; PP — pulse pressure; 
SBP — systolic blood pressure 
 
